Sign in

YBGJ on OTC

Yubo International Biotech Ltd

Yubo International Biotech Ltd is a U.S. holding company primarily operating through our wholly owned subsidiary.1 It is headquartered in Beijing, China.1 Its shares trade on OTC under the symbol YBGJ.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with ENDRA Life Sciences Inc., ENDONOVO THERAPEUTICS, INC. or Nexalin Technology, Inc., or pick any stock.

  • TickerYBGJ on OTC1
  • IndustryElectromedical & Electrotherapeutic Apparatus1
  • HeadquartersBeijing, China1
  • Incorporated inNY2
  • Business addressRoom 105, Building 5, 31 Xishiku Avenue, Beijing, F4 000002
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a U.S. holding company primarily operating through our wholly owned subsidiary, Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands (“Platinum”). Platinum is not a Chinese operating company but a Cayman Islands holding company, which in turn operates in China through its subsidiaries and contractual arrangements with a variable interest entity (“VIE”), Yubo International Biotech (Beijing) Limited, a company organized under the laws of the People’s Republic of China and which is, through contractual arrangements with us, the Chinese operating company (“Yubo Beijing”). None of our Company, Platinum, or Platinum International Biotech (Hong Kong) Limited, a wholly owned subsidiary of Platinum (“Platinum HK”), each as a holding company, conducts any day-to-day business operations in China.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

66.1%Gross margin4
-9614.6%Operating margin4
-8736.7%Net margin4
256.0%Revenue growth, 20254

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue34¢$4.2K
  • Other costs66¢$8.2K

Out of $12.4K in revenue.4 The company lost money this year.

Financial statements

Revenue56784$12.4K in 2025
0$500.0K$1.0M$1.5M2019: $0$020192020: $0$020202021: $1.2M$1.2M20212022: $104.3K$104.3K2022−92%2023: $604.7K$604.7K2023+480%2024: $3.5K$3.5K2024−99%2025: $12.4K$12.4K2025+256%
Gross profit96784$8.2K in 2025−99% since 2020
0$500.0K$1.0M$1.5M2020: $1.2M$1.2M20202021: $820.6K$820.6K2021−34%2022: $52.7K$52.7K2022−94%2023: $419.2K$419.2K2023+696%2024: $2.6K$2.6K2024−99%2025: $8.2K$8.2K2025+208%
Operating income596784-$1.2M in 2025+2374% since 2019
-$2.0M-$1.5M-$1.0M-$500.0K02019: -$48.0K-$48.0K20192020: -$711.8K-$711.8K2020+1383%2021: -$1.5M-$1.5M2021+117%2022: -$1.2M-$1.2M2022−22%2023: -$1.2M-$1.2M2023−1%2024: -$1.8M-$1.8M2024+48%2025: -$1.2M-$1.2M2025−33%
Net income596784-$1.1M in 2025+629% since 2019
-$2.0M-$1.5M-$1.0M-$500.0K02019: -$148.0K-$148.0K20192020: -$711.8K-$711.8K2020+381%2021: -$1.5M-$1.5M2021+117%2022: -$1.2M-$1.2M2022−22%2023: -$1.2M-$1.2M2023−1%2024: -$1.8M-$1.8M2024+49%2025: -$1.1M-$1.1M2025−39%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Sales of products and services$12.4K$3.5K
Cost of goods and services sold-$4.2K-$822
Gross Profit$8.2K$2.6K
Employee compensation$766.9K$857.4K
Occupancy$116.0K$390.1K
Depreciation and amortization of property and equipment$167.6K$169.9K
Amortization of intangible assets$10.2K$13.4K
Other operating expenses$135.2K$341.8K
Total Operating Expenses$1.2M$1.8M
Loss from operations-$1.2M-$1.8M
Loss on obsolescence inventory$0-$211.9K
Interest income (expense)-$243$50
Total Other Income (Expenses)-$243-$211.9K
Loss before Provision for Income Tax-$1.2M-$2.0M
Provision for Income Tax$0$0
Net loss-$1.2M-$2.0M
Net loss attributable to non-controlling interest-$108.7K-$206.5K
Net loss attributable to common stockholders-$1.1M-$1.8M
Net loss per share basic and diluted-$0.01-$0.02
Weighted average common shares outstanding basic and diluted139.6M shares119.8M shares
Net loss to the Company-$1.1M-$1.8M
Net loss to non-controlling interests-$108.7K-$206.5K
Foreign currency translation adjustment to the Company$19.1K$140.2K
Foreign currency translation adjustment to non-controlling interests-$7.6K$13.0K
Total comprehensive loss-$1.2M-$1.8M

Compare Yubo International Biotech Ltd with another company

Corporate structure

Yubo International Biotech Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Yubo International Biotech Ltd

  • Chinaone Technology Ltd Filed SCHEDULE 13D/A on Yubo International Biotech Ltd, latest Jul 25, 2025 (2 filings since Apr 25, 2025)
  • Flydragon International Ltd Filed SCHEDULE 13D/A on Yubo International Biotech Ltd, latest Jul 25, 2025
  • Boao Biotech Ltd Filed SCHEDULE 13G on Yubo International Biotech Ltd, latest Jun 3, 2025
  • Focus Draw Group Ltd Filed SC 13D/A on Yubo International Biotech Ltd, latest Nov 10, 2022
  • Ho Shun Cheung Filed SC 13G on Yubo International Biotech Ltd, latest Nov 10, 2022
  • Yubo International Biotech Ltd Beijing, China

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Yubo International Biotech Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$21.4K4 Dec 31, 2025$21.4K4 Dec 31, 20240%
Computer equipment and software$33.9K4 Dec 31, 2025$33.9K4 Dec 31, 20240%
Leasehold improvements$187.2K4 Dec 31, 2025$187.2K4 Dec 31, 20240%
Construction in progress$18.9K4 Dec 31, 2025$18.9K4 Dec 31, 20240%
Property and equipment, before depreciation$227.5K4 Dec 31, 2025$227.5K4 Dec 31, 20240%
Accumulated depreciation$184.5K4 Dec 31, 2025$21.6K4 Dec 31, 2024+754.4%
Property and equipment, net$43.0K4 Dec 31, 2025$205.9K4 Dec 31, 2024−79.1%
Operating-lease assets (leased space)$78.8K4 Dec 31, 2025$478.8K4 Dec 31, 2024−83.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.1K4 Dec 31, 2025$7.0K8 Dec 31, 2024+14.9%
Deposits held (banks)$71.1K4 Dec 31, 2025$68.5K8 Dec 31, 2024+3.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$42.1K4 Dec 31, 2025$50.5K4 Dec 31, 2024−16.7%
Finite-lived intangibles, gross$94.5K4 Dec 31, 2025$94.5K4 Dec 31, 20240%
Accumulated amortization-$52.4K4 Dec 31, 2025-$44.0K4 Dec 31, 2024−19.2%
Finite-lived intangibles, net$42.1K4 Dec 31, 2025$50.5K4 Dec 31, 2024−16.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$24.0K4 Dec 31, 2025$37.0K4 Dec 31, 2024−35.0%

Properties, in its own words

Yubo Beijing’s headquarters are located at Room 1102, 11th Floor, Building 2, No. 10 Chaoyang Park South Road, Chaoyang District, Beijing, PRC and consist of approximately 290 square meters of office space. The lease for Yubo Beijing’s headquarters has an initial term of two years commencing on August 5, 2024. The lease also provides for monthly rent and management fees totaling RMB55,000 (approximately $7,825 at an exchange rate of RMB7.0288=US$1.00 as of December 31, 2025).

In April 2024, Yubo Shenzhen entered into two agreements with Shenzhen Material Group Co., Ltd. to lease (i) 712 square meter office space in Shenzhen at a monthly rent of RMB97,686 (approximately $13,898 at an exchange rate of RMB7.0288=US$1.00 as of December 31, 2025). The lease term commenced on April 1, 2024 and was due to expire on March 14, 2026. After consultation, both parties signed a termination agreement on January 25, 2025; and (ii) 160 square meter office space in Shenzhen at a monthly rent of RMB17,280 (approximately $2,458 at an exchange rate of RMB7.0288=US$1.00 as of December 31, 2025). The lease commenced on April 1, 2024 and was due to expire on November 17, 2025. However, the agreement was terminated on November 1, 2024.

The rest of Item 2

Effective September 1, 2021, Yubo Jingzhi entered into an agreement with Sichuan Anyi Hengke Tech Co., Ltd. to lease approximately 1,282 square meters of laboratory space in Chengdu, China. The lease provides for a lease term from September 1, 2021 to February 28, 2026 at monthly rent payment of RMB 58,449 (approximately $8,315 at an exchange rate of RMB7.0288 =US$1.00 as of December 31, 2025). As of the date of this Annual Report, the contract has expired, and negotiations are underway for renewal.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led Yubo International Biotech Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Wang Jun2020–2021
  2. Wang Yang2025–now

President

  1. Wang Jun2020–now

Chief financial officer

  1. Lina Liu2020–2022
2010201520202025
  • Chief executive officerWang Yang Jun 2, 2025 to now13
  • Chief executive officerWang Jun Oct 16, 2020 to Jan 20, 202114
  • PresidentWang Jun Oct 16, 2020 to now14
  • Chief financial officerLina Liu Oct 15, 2020 to Nov 10, 202215
Board members and other officers (6)

Former names

  • MAGNA LAB INCJun 28, 1996 to Dec 4, 20202

Timeline

  1. Jan 16, 20268-K Change of auditor21
  2. Jul 25, 20258-K Entered a material agreement; Unregistered sale of shares22
  3. Jun 2, 2025New chief executive Wang Yang becomes CEO13
  4. Jan 10, 20258-K Change of auditor23
  5. Jan 6, 20258-K Change of auditor24
  6. Dec 7, 20228-K Entered a material agreement25
  7. Nov 10, 20228-K Regulation FD disclosure; Other events26
  8. Sep 9, 20228-K Entered a material agreement27
  9. Oct 16, 2020New chief executive Wang Jun becomes CEO14

Filings

74 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 7 major events, 7 insider forms, 6 large holders, 34 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. Jun 12, 2026ARS EDGAR
  3. Jun 12, 2026DEF 14C EDGAR
  4. May 15, 202610-Q EDGAR
  5. Mar 31, 202610-K EDGAR
  6. Jan 16, 20268-K EDGAR
  7. Nov 14, 202510-Q EDGAR
  8. Aug 13, 202510-Q EDGAR
  9. Jul 25, 20254 EDGAR
  10. Jul 25, 20254 EDGAR
  11. Jul 25, 2025SCHEDULE 13D/A EDGAR
  12. Jul 25, 2025SCHEDULE 13D/A EDGAR
  13. Jul 25, 20258-K EDGAR
  14. Jun 3, 2025SCHEDULE 13G EDGAR
  15. Jun 3, 20254 EDGAR
  16. Jun 2, 20254 EDGAR
  17. May 14, 202510-Q EDGAR
  18. May 5, 20253 EDGAR
  19. Apr 25, 2025SCHEDULE 13D/A EDGAR
  20. Apr 14, 2025DEF 14C EDGAR

The 74 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 0 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 15, 2024Wang YangChief Executive OfficerSale2,000,000$0.12$240.0KForm 4
Jan 25, 2024CAO YULIN10% ownerSale5,040,140$0.30$1.5MForm 4
Nov 9, 2022Liu LinaChief Financial OfficerSale4,728,000$0.50$2.4MForm 4
Sep 23, 2022Focus Draw Group LtdSale4,728,000$0.50$2.4MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Yubo International Biotech Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARYubo International Biotech Ltd1
  • CIK0000895464
  • Employer ID (EIN)11-30743263
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNew York3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business addressRoom 105, Building 5, 31 Xishiku Avenue, Beijing, F4 000001
  • Phone86 (010) 6615-51411
  • Shares outstanding170,416,343 shares as of Mar 25, 20263
  • Public float$1 as of Jun 30, 20253
  • AuditorHCL PLLC, Chicago, IL PCAOB ID 7269; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMay 29, 19961
  • Filings284 in all: 10-Q (56), 10QSB (36), 8-K (23), NT 10-K (21), NT 10-Q (19), 10-K (17), 4 (15), 10KSB (13)1
    All 32 form types

    UPLOAD (12), SC 13D (11), 3 (10), S-1/A (9), DEF 14C (5), CORRESP (4), PRE 14C (4), 424B3 (3), 8-K/A (3), DEF 14A (3), SCHEDULE 13D/A (3), PRE 14A (2), S-8 (2), SC 13D/A (2), SC 14F1 (2), 10-KT (1), 10-Q/A (1), 10QSB/A (1), ARS (1), EFFECT (1), PRER14A (1), S-1 (1), SC 13G (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Aug 8, 2001
    Latest 8-K (8-K) Jan 16, 2026

Risk factors and legal proceedings

The risks Yubo International Biotech Ltd names in Item 1A of its 10-K filed Mar 31, 2026: 47 risks under these headings, as written.3

  • Risks Related to our Corporate Structure
  • Our contractual arrangements with Yubo Beijing and its shareholders may not be as effective in providing management over these entities as direct ownership.
  • Transactions among our affiliates are subject to scrutiny by the PRC tax authorities and a finding that we or any of our consolidated entities owe additional taxes could have a material adverse impact on our net income.
  • Risks Related to Doing Business in China
  • The PRC government has significant authority to exert influence on the China operations of an offshore holding company, such as us. Therefore, Yubo Beijing’s business face potential uncertainty from the PRC government’s policy. Changes in China’s economic, political or social conditions, or government policies could materially and adversely affect our or Yubo Beijing’s business, financial condition, and results of operations.
  • Yubo Beijing’s business might be subject to various evolving PRC laws and regulations regarding cybersecurity, data privacy and data security. Failure of cybersecurity, data privacy and data security compliance could subject Yubo Beijing to penalties, damage its reputation and brand and harm its business and results of operations.
  • The approval of the CSRC or other PRC government authorities may be required in connection with future offshore offering under PRC law, and, if so required, we cannot predict whether or for how long Yubo Beijing will be able to obtain such approval. Any failure to obtain or delay in obtaining such approval for an offshore offering would subject Yubo Beijing to sanctions imposed by the CSRC or other PRC government authorities.
  • The medical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of Yubo Beijing’s products and services.
  • Yubo Beijing faces risks associated with uncertainties relating to Regulation for the Administration of Human Genetic Resources.
  • Adverse global economic conditions and geopolitical tensions could negatively impact Yubo Beijing or our business operations in China.
  • New or threatened U.S. tariffs could increase costs and disrupt Yubo Beijing or our operations in China.
  • You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management named in this Annual Report based on foreign laws.
The other 37 risks
  • It may be difficult for overseas regulators to conduct investigations or collect evidence within China.
  • The Holding Foreign Companies Accountable Act, or the HFCA Act, and the related regulations are evolving quickly. Further implementations and interpretations of or amendments to the HFCA Act or the related regulations, or a PCAOB’s determination of its lack of sufficient access to inspect our auditor, might pose regulatory risks to and impose restrictions on us because of Yubo Beijing’s operations in mainland China, and you may be deprived of the benefits of such inspection and our stocks could be delisted from the stock exchange pursuant to the HFCA Act.
  • Dividends we receive from our subsidiaries located in the PRC may be subject to PRC withholding tax, which could materially and adversely affect the amount of dividends, if any, we may pay our shareholders.
  • If we are classified as a “resident enterprise” of China under the PRC Enterprise Income Tax Law, we and our non-PRC shareholders could be subject to unfavorable tax consequences, and our business, financial condition and results of operations could be materially and adversely affected.
  • Restrictions on foreign exchange and the ability to transfer cash between entities, across borders and to U.S. investors may affect the value of your investment.
  • Fluctuation in exchange rates could have a negative effect on our results of operations and the value of your investment.
  • PRC regulations relating to offshore investment activities by PRC residents and enterprises may increase our administrative burden and restrict our overseas and cross-border investment activity. If our PRC resident and enterprise shareholders fail to make any required applications and filings under such regulations, we may be unable to distribute profits to such shareholders and may become subject to liability under PRC law.
  • The M&A Rules and certain other PRC regulations establish complex procedures for some acquisitions of PRC companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China.
  • We and our shareholders face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises, assets attributed to a PRC establishment of a non-PRC company or immovable properties located in China owned by non-PRC companies.
  • Risks Related to Shares of our Common Stock
  • The relative lack of U.S. public company experience of our management team may put us at a competitive disadvantage.
  • Our common stock is not listed on any stock exchange and there is a limited market for shares of our common stock. Even if a market for our common stock develops, our common stock could be subject to wide fluctuations.
  • We cannot assure you that our common stock will become eligible for listing or quotation on any national stock exchange and the failure to do so may adversely affect your ability to dispose of our common stock in a timely fashion.
  • Our common stock may be subject to penny stock rules, which may make it more difficult for our stockholders to sell their common stock.
  • FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.
  • We do not anticipate paying any cash dividends in the foreseeable future.
  • We may need additional capital, and the sale of additional shares or other equity securities, including our Class B common stock, could result in additional dilution to our stockholders.
  • Our dual-class voting structure will limit your ability to influence corporate matters and could discourage others from pursuing any change of control transactions that holders of our Class A common stock may view as beneficial.
  • Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
  • We have a substantial number of authorized common shares available for future issuance that could cause dilution of our stockholders’ interest and adversely impact the rights of holders of our common stock.
  • Risks Related to our Business and Industry
  • We may encounter difficulties in recruiting and retaining eligible donors for our stem cell bank and clinical trials, and the collection and storage of biological samples subject us to strict data privacy and security regulations.
  • The commercial success of Yubo Beijing’s products depends upon the degree of their market acceptance among the medical community. If Yubo Beijing’s products do not attain market acceptance among the medical community, its operations and profitability would be adversely affected.
  • We have a history of losses and may continue to incur losses in the future, which raises substantial doubt about our ability to continue as a going concern.
  • Yubo Beijing’s proprietary, next-generation stem cell derived technologies, approach for stem cell storage facilities and manufacturing platform for its stem cell based products, represent emerging approaches to medical treatments that face significant challenges and hurdles.
  • Yubo Beijing may not be able to successfully create its own manufacturing infrastructure and stem cell storage facilities for supply and maintenance of its requirements of programmed stem cell products for use in clinical trials and for commercial sale.
  • Yubo Beijing may not be able to timely identify or otherwise effectively respond to changing customer preferences, and Yubo Beijing may fail to optimize its product offering and inventory position.
  • Yubo Beijing faces significant competition, and if Yubo Beijing does not compete successfully against existing and new competitors, Yubo Beijing’s revenue and profitability would be materially and adversely affected.
  • Yubo Beijing relies on a small number of customers for a significant percentage of its revenue, and the loss of, or a reduction in, orders from these customers could result in a substantial decline in its revenue.
  • Yubo Beijing relies on third-party manufacturers to supply all of its light application products.
  • Yubo Beijing’s certificates, permits, and licenses related to its business are subject to governmental control and renewal and failure to obtain renewal will cause all or part of its operations to be terminated.
  • If Yubo Beijing is unable to protect its intellectual property from infringement, Yubo Beijing’s business and prospects may be harmed.
  • Yubo Beijing may acquire other businesses, license rights to products or form alliances with third-parties, which could cause it to incur significant expenses and could negatively affect its profitability.
  • Our executive officers and directors have existing responsibilities and, in the future, may have additional responsibilities, to provide management and services to other entities in addition to us. As a result, conflicts of interest between us and the other activities of those persons may occur from time to time and could have an adverse effect on us.
  • General Risk Factors
  • We are subject to the reporting obligation and internal control requirements of federal securities laws, which is expensive and time-consuming.
  • Volatility in our common stock price may subject us to securities litigation.
  • If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.
  • We are subject to critical accounting policies and actual results may vary from our estimates.
  • We may need additional capital and may not be able to obtain it on acceptable terms or at all, which could adversely affect our liquidity and financial position; the issuance of additional equity would result in dilution to our shareholders.

Legal proceedings

We and Yubo Beijing are currently not a party to any material legal or administrative proceedings. We or Yubo Beijing may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of our and Yubo Beijing’s business, including matters involving product qualities, among others. Any litigation or other legal or administrative proceedings, regardless of the outcome, are likely to result in substantial costs and a diversion of our or Yubo Beijing’s resources, including the management’s time and attention.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32